References
- Chaplin S, Birkedal MF, Crilly E, et al. Haemophilia specialist nurses’ perceptions of haemophilia B. J Haem Pract 2021; 8(1): 119–127. doi: 10.2478/jhp-2021-0013.
- Garner K, Guelcher C, Pollard D. The use of rIX-FP in patients with haemophilia B: A nurses’ perspective. J Haem Pract 2021; 8(1): 86–97. doi: 10.17225/jhp00180.
- Murphy SL, High KA. Gene therapy for haemophilia. Br J Haematol 2008; 140(5): 479–87. doi: 10.1111/j.1365-2141.2007.06942.x.
- UCL research leads to haemophilia gene therapy success. 15 December 2017. UCL. Available at https://www.ucl.ac.uk/news/2017/dec/ucl-research-leads-haemophilia-gene-therapy-success (accessed 27 September 2021).
- Mann DM, Stafford KA, Poon MC, Matino D, Stafford DW. The Function of extravascular coagulation factor IX in haemostasis. Haemophilia 2021; 27(3): 332–339. doi: 10.1111/hae.14300.
- Castaman G. The benefits of prophylaxis in patients with hemophilia B. Expert Rev Hematol 2018; 11(8): 673–683. doi: 10.1080/17474086.2018.1489719.
- Srivastava A, Santagostino E, Dougall A, et al.; WFH Guidelines for the Management of Hemophilia panellists and co-authors. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 Suppl 6: 1–158. doi: 10.1111/hae.14046.
- Valentino L, Blanchett V, Negrier C, et al. Personalising haemophilia management with shared decision making. J Haem Pract 2021; 8(1): 69–79. doi: 10.17225/jhp00178.
- Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014; 371(21): 1994–2004. doi:10.1056/NEJMoa1407309.
- Von Drygalski A, Giermasz A, Castaman G, et al. Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B. Blood Adv 2019; 3(21): 3241–3247. doi: 10.1182/bloodadvances.2019000811.